Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 71 entries
View as:

Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy

Phase: N/A Priority: Normal
NCT ID: NCT04430192 Org: User:
Start: 08/06/20 End: 08/30/25 Due: 08/30/26

A Trial of Pamiparib With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects

Phase: N/A Priority: Normal
NCT ID: NCT04985721 Org: User:
Start: 02/24/22 End: 08/01/25 Due: 08/01/26

Stereotactic Ablative Body Radiotherapy (SABR) with Maintenance of Systemic Therapy Versus Physicians' Choice of Systemic Therapy for Oligoprogressive ER-positive, Her-2 Negative Breast Cancer II

Phase: N/A Priority: Normal
NCT ID: NCT06882499 Org: User:
Start: 05/01/25 End: 02/29/32 Due: 02/28/33

EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T

Phase: N/A Priority: Normal
NCT ID: NCT05521412 Org: User:
Start: 09/29/22 End: 12/31/26 Due: 12/31/27

PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours

Phase: N/A Priority: Normal
NCT ID: NCT05053854 Org: User:
Start: 12/08/21 End: 06/30/29 Due: 06/30/30

Phase 0 of 18F FPM Using PET/CT in Patients With a Variety of Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT01755650 Org: User:
Start: 10/31/11 End: 11/03/17 Due: 11/03/18

Avelumab With Chemoradiation in Locally Advanced Rectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03299660 Org: User:
Start: 04/30/18 End: 02/28/23 Due: 02/28/24

Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE

Phase: N/A Priority: Normal
NCT ID: NCT04720768 Org: User:
Start: 06/04/20 End: 12/04/24 Due: 12/04/25

In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT04343885 Org: User:
Start: 04/21/20 End: 04/30/24 Due: 04/30/25

Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05340374 Org: User:
Start: 07/14/22 End: 12/31/26 Due: 12/31/27

Invasive Fungal Infections in Patients Following Stem Cell Transplant

Phase: N/A Priority: Normal
NCT ID: NCT04619147 Org: User:
Start: 01/15/22 End: 04/20/24 Due: 04/20/25

COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;

Phase: N/A Priority: Normal
NCT ID: NCT04534725 Org: User:
Start: 12/17/20 End: 04/19/23 Due: 04/19/24

Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475

Phase: N/A Priority: Normal
NCT ID: NCT02303366 Org: User:
Start: 09/30/15 End: 04/30/17 Due: 04/30/18

A Phase II Study to Determine Pembrolizumab as Frontline Treatment of Patients With Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT03331731 Org: User:
Start: 11/29/18 End: 07/31/24 Due: 07/31/25

FAPI-CUP- Evaluating FAPI as a Novel Radiopharmaceutical for Cancer of Unknown Primary

Phase: N/A Priority: Normal
NCT ID: NCT05263700 Org: User:
Start: 02/23/22 End: 02/22/24 Due: 02/22/25

Metabolic Phenotypes in Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT05570227 Org: User:
Start: 06/27/23 End: 10/31/27 Due: 10/31/28

A Prospective Single Arm Study of Intraoperative Radiotherapy for Locally Advanced or Recurrent Rectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01493206 Org: User:
Start: 07/31/04 End: 08/31/11 Due: 08/31/12

Panobinostat Biological Correlates Study

Phase: N/A Priority: Normal
NCT ID: NCT01658241 Org: User:
Start: 07/16/12 End: 03/18/15 Due: 03/18/16

Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02506556 Org: User:
Start: 09/07/15 End: 10/26/21 Due: 10/26/22

Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With Zanubrutinib

Phase: N/A Priority: Normal
NCT ID: NCT06812715 Org: User:
Start: 05/31/25 End: 05/31/31 Due: 05/31/32

ProsTIC Registry of Men Treated With PSMA Theranostics

Phase: N/A Priority: Normal
NCT ID: NCT04769817 Org: User:
Start: 05/01/21 End: 12/31/28 Due: 12/31/29

Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT03302728 Org: User:
Start: 08/30/18 End: 08/02/21 Due: 08/02/22

Perioperative Pharmacogenomic Testing

Phase: N/A Priority: Normal
NCT ID: NCT05063838 Org: User:
Start: 11/29/21 End: 07/31/24 Due: 07/31/25

A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT00431990 Org: User:
Start: 11/30/06 End: 01/31/12 Due: 01/31/13

A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)

Phase: N/A Priority: Normal
NCT ID: NCT04914741 Org: User:
Start: 06/29/21 End: 07/31/25 Due: 07/31/26